When Will CBX-11 Enter The Clinic: Clinical Program Starting In January Or February Of 2020

When Will CBX-11 Enter The Clinic: Clinical Program Starting In January Or February Of 2020

Annual-Meeting

5 months
131 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses When Will CBX-11 Enter The Clinic: Clinical Program Starting In January Or February Of 2020. BACKROUND: Poly(ADP-ribose)polymerase inhibitors (PARPis) are a promising new class of anti-cancer agents, but their clinical application has largely been limited to tumors with homologous recombination deficiency (HRD), such as those with BRCA1/2 mutations. One strategy to target HRD-negative tumors with PARPis is to combine them with chemotherapy, although clinical trials indicate that dose-limiting toxicities are a major barrier to achieving synergistic efficacy with these combinations. METHODS: We sought to test the hypothesis that HRD-negative cancers can be effectively treated with tumor-targeted PARPis in combination with chemotherapy, using our recently developed alphalex platform. This platform allows small molecule anti-cancer agents to penetrate cell membranes only at the low pH associated with the tumor microenvironment and tumor cells, directly delivering drugs to tumors while sparing normal tissue. We tested whether alphalex PARPi-conjugates in combination with chemotherapy could selectively kill cancers independent of HRD status, using a range of in vitro and in vivo tumor models. RESULTS: We conjugated a diverse range of structurally unique PARPis using the alphalex platform, and demonstrated that these molecules are delivered directly into tumor cells in a pH-dependent manner. We observed significant reductions in PARylation activity and exquisite synergy with DNA damaging agents in vitro. We then demonstrated that alphalex-PARPi conjugates in combination with both temozolomide (TMZ) and irinotecan induce significant tumor cell killing in HRD-negative tumors in vivo. Importantly, we found that our tumor-targeting approach significantly reduced normal tissue toxicity, with almost complete sparing of the bone marrow relative to TMZ alone. CONCLUSIONS: The alphalex platform enables PARPi combinations with clinically relevant chemotherapies, as a means to target HRD-negative cancers without significant bone marrow toxicity. Based on these successful proof-of-concept data, we are now performing IND-enabling studies for an alphalex PARPi conjugate (CBX-11), and we anticipate initiating a Phase I clinical trial in January 2020 in solid tumors independent of HRD status.
Up Next Autoplay
Surgical Trial for RCC @CleClinicMD
Surgical Trial for RCC @CleClinicMD
Category: Kidney Cancer
0 Views
Cleveland Clinic 4 minutes
Phase 1/2 AUGMENT-101 Trial @sloan_kettering
Phase 1/2 AUGMENT-101 Trial @sloan_kettering
Category: Acute Lymphoblastic Leukemia
0 Views
Memorial Sloan Kettering 58 minutes
Do We Still Need The P-Value? @MDAndersonNews
Do We Still Need The P-Value? @MDAndersonNews
Category: Kidney Cancer
6 Views
kidneycancer 21 hours
Circulating Tumor DNA (ctDNA) Results in 110 Patients with Advanced Clear Cell Renal Cell Carcinoma
Circulating Tumor DNA (ctDNA) Results in 110 Patients with Advanced Clear Cell Renal Cell Carcinoma
Category: Kidney Cancer
7 Views
kidneycancer 22 hours
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Category: Non-Hodgkin Lymphoma
1 Views
Cancer-News 23 hours
Importance of Paradigms for Precision Medicine @sloan_kettering
Importance of Paradigms for Precision Medicine @sloan_kettering
Category: News
0 Views
Memorial Sloan Kettering 23 hours
Precision Medicine in Epichaperome Cancer Therapy @sloan_kettering
Precision Medicine in Epichaperome Cancer Therapy @sloan_kettering
Category: News
2 Views
Memorial Sloan Kettering 1 day
Myovant Sciences reports 97% Response rate in Phase 3 HERO Once-Daily Study, Oral Relugolix in Advanced Prostate Cancer Men
Myovant Sciences reports 97% Response rate in Phase 3 HERO Once-Daily Study, Oral Relugolix in Advanced Prostate Cancer Men
Category: Prostate Cancer
7 Views
Cancer-News 1 day
Anti–PD-1/PD-L1 Antibody Immunotherapy: Will This Affect Clinicians Today?
Anti–PD-1/PD-L1 Antibody Immunotherapy: Will This Affect Clinicians Today?
Category: Immunotherapy
4 Views
Cleveland Clinic 1 day
POSEIDON Reaps Success for Imfinzi in Non-Small Cell Lung Cancer from AstraZeneca, GlobalData says
POSEIDON Reaps Success for Imfinzi in Non-Small Cell Lung Cancer from AstraZeneca, GlobalData says
Category: Non-Small Cell Lung Cancer
1 Views
Cancer-News 1 day